Organon & Co. (NYSE:OGN) (NYSE: OGN) is a global healthcare company with roots tracing back to the original Organon founded in 1923. The company began independent operations on June 3, 2021, following its spin-off from Merck & Co., Inc. Headquartered in Jersey City, New Jersey, and domiciled in Dublin, Ireland, Organon is committed to advancing health for women and broader patient populations through a focused portfolio of medicines and therapies.
Organon’s business is organized into three main segments: women’s health, biosimilars and established medicines. Its women’s health franchise includes contraceptives, fertility treatments, hormone replacement therapies and products for conditions such as endometriosis, osteoporosis and uterine fibroids. The biosimilars division develops and manufactures cost-effective versions of biologic therapies for chronic and complex diseases, while the established medicines segment markets a broad range of branded and generic pharmaceuticals in areas such as cardiovascular, respiratory, dermatology and anesthesia.
The company operates in more than 140 countries across North America, Europe, Latin America, Asia Pacific and the Middle East. Organon maintains research, development and manufacturing facilities in key regions and partners with local distributors and healthcare organizations to ensure regulatory compliance, market access and patient support. This global footprint enables the company to tailor its offerings to diverse healthcare systems and patient needs worldwide.
Led by President and Chief Executive Officer Kevin Ali and a seasoned executive team, Organon prioritizes research-driven innovation, operational excellence and sustainable growth. The company continues to invest in its pipeline, forging strategic collaborations and pursuing digital health initiatives, while upholding commitments to corporate responsibility, patient education and community outreach in support of its mission to enhance health outcomes globally.
